Literature DB >> 15454616

Supplemental oxygen causes increased signal intensity in subarachnoid cerebrospinal fluid on brain FLAIR MR images obtained in children during general anesthesia.

Chantal Frigon1, Dennis W W Shaw, Susan R Heckbert, Edward Weinberger, David S Jardine.   

Abstract

PURPOSE: To prospectively test the hypothesis that high levels of the fraction of inspired oxygen (Fio(2)) during general anesthesia cause subarachnoid cerebrospinal fluid (CSF) hyperintensity during fluid-attenuated inversion-recovery (FLAIR) magnetic resonance (MR) imaging.
MATERIALS AND METHODS: At brain MR imaging during general anesthesia with propofol, two FLAIR sequences were performed in 20 children with American Society of Anesthesiologists physical status classification system grades of 3 or lower. The first FLAIR sequence was performed with the child breathing 100% oxygen; the second was performed with the child breathing 30% oxygen. CSF signal intensity was quantified on a three-point ordinal scale (0 = hypointense to brain parenchyma, 1 = isointense to brain parenchyma, 2 = hyperintense to brain parenchyma) by a pediatric neuroradiologist who was blinded to the Fio(2) level. The Wilcoxon signed rank test was used to determine if CSF hyperintensity was correlated with Fio(2).
RESULTS: CSF hyperintensity was present in all 20 children (age range, 1.9-16.7 years; 12 children were boys) when the Fio(2) was 100%. The hyperintensity partially or completely disappeared in the basilar cisterns (P <.001) and cerebral sulcal subarachnoid space (P <.001) after Fio(2) was reduced from 100% to 30%.
CONCLUSION: These findings are consistent with the hypothesis that increased arterial oxygen tension and consequently increased CSF Po(2) resulting from administration of high Fio(2) during general anesthesia are responsible for the increased CSF signal intensity noted on brain FLAIR MR images. Copyright RSNA, 2004

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15454616     DOI: 10.1148/radiol.2331031375

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  7 in total

1.  Observation of contrast enhancement in the cochlear fluid space of healthy subjects using a 3D-FLAIR sequence at 3 Tesla.

Authors:  Shinji Naganawa; Tomomi Komada; Hiroshi Fukatsu; Takeo Ishigaki; Osamu Takizawa
Journal:  Eur Radiol       Date:  2005-11-03       Impact factor: 5.315

Review 2.  Imaging of accidental paediatric head trauma.

Authors:  Phua Hwee Tang; Choie Cheio Tchoyoson Lim
Journal:  Pediatr Radiol       Date:  2009-01-06

3.  Reduction of Oxygen-Induced CSF Hyperintensity on FLAIR MR Images in Sedated Children: Usefulness of Magnetization-Prepared FLAIR Imaging.

Authors:  H-K Jeong; S W Oh; J Kim; S-K Lee; S J Ahn
Journal:  AJNR Am J Neuroradiol       Date:  2016-03-17       Impact factor: 3.825

4.  Elevated cerebral blood volume contributes to increased FLAIR signal in the cerebral sulci of propofol-sedated children.

Authors:  J H Harreld; N D Sabin; M G Rossi; R Awwad; W E Reddick; Y Yuan; J O Glass; Q Ji; A Gajjar; Z Patay
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-03       Impact factor: 3.825

5.  Delayed CSF enhancement in posterior reversible encephalopathy syndrome.

Authors:  B E Hamilton; G M Nesbit
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-09       Impact factor: 3.825

6.  Dynamic oxygen-enhanced MRI of cerebrospinal fluid.

Authors:  Taha M Mehemed; Yasutaka Fushimi; Tomohisa Okada; Akira Yamamoto; Mitsunori Kanagaki; Aki Kido; Koji Fujimoto; Naotaka Sakashita; Kaori Togashi
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

7.  Proper fraction of inspired oxygen for reduction of oxygen-induced canine cerebrospinal fluid hyperintensity on fluid attenuation inversion recovery sequence using low-field magnetic resonance imaging.

Authors:  Moonjung Jang; Jaewoo Hwang; Jihye Nam; Dalhae Kim; Wongyun Son; Inhyung Lee; Mincheol Choi; Junghee Yoon
Journal:  J Vet Med Sci       Date:  2020-07-20       Impact factor: 1.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.